Swedish Company, Diamyd Medical AB, Plans to Have Diabetes Vaccine by 2011

Shares

Diamyd Medical AB, a Swedish diabetes company focusing on the development of pharmaceuticals for the treatment of autoimmune diabetes and its complications, announced it plans to file the Diamyd® diabetes vaccine for market approval in 2011.

The European Phase III study with Diamyd® has been fully recruited meaning that the first results from the study can be reported during spring 2011. A recruitment campaign for the US study has been launched together with the recruitment firm Inclinix under the name DiaPrevent, and the number of patients recruited for the study is increasing at a fast pace.

2
Leave a Reply

avatar
3000
2 Comment threads
0 Thread replies
0 Followers
 
Most reacted comment
Hottest comment thread
2 Comment authors
ElenorAlbert Recent comment authors
  Subscribe  
newest oldest most voted
Notify of
Elenor
Elenor

Albert,
I think you will find the answer here at Diamyd´s website.
http://www.diamyd.com/
Shortly, the Diamyd vaccin seems to stop the immune attack  which is  killing the beta cells. 

Albert
Albert

How could Diamyd Medical produce a vaccine to prevent and treat type 1 diabetes when  no one knows what causes type 1 diabetes in the first place.

Copyright © 2009-2018 Diabetes Media Foundation, All Rights Reserved.
ASweetLife™ is a trademark of the Diabetes Media Foundation, All Rights Reserved.